Your EDR Is Not Failing. Your Response Model Is.
Many biotech executives believe they have endpoint protection because they bought EDR.
That belief is dangerous.
EDR can detect suspicious behavior. It can isolate a machine. It can produce alerts, timelines, process trees, and forensic clues. But none of that means your company is protected if nobody is watching, nobody is accountable, and nobody can make a fast containment decision when the alert matters.
This is where many biotech companies under $100M have a quiet security problem. They are not reckless. They are not ignoring cybersecurity. They have tools. They have IT people. They may even have a modern endpoint platform. But they are depending on technology to compensate for an immature response model.
That is not protection. That is delayed decision-making dressed up as security.
For biotech, delay is not a technical inconvenience. It can become a business event.
A compromised endpoint in a normal business may expose email, credentials, or financial data. A compromised endpoint in biotech may sit near research data, trial documentation, intellectual property, lab systems, vendor portals, regulated records, or executive communications tied to funding, partnerships, or acquisition activity. The asset value is different. The consequences are different.
The uncomfortable truth is this: if your team cannot consistently triage, validate, escalate, contain, and document endpoint alerts 24×7, your EDR is only giving you the opportunity to respond. It is not guaranteeing that response happens.
That distinction matters.
Verizon’s 2026 Data Breach Investigations Report notes that 31% of breaches now start with software vulnerabilities, and 48% involve ransomware. Attackers are not waiting for your IT team’s next available maintenance window. They exploit gaps, move quickly, and look for environments where the alert-to-action process is slow or unclear.
Most biotech security leaders already understand this at a technical level. The real issue is operational.
Who gets the alert at 11:47 p.m. on a Saturday?
Who decides whether the endpoint should be isolated?
Who checks whether the same activity is appearing on other machines?
Who reviews identity activity, VPN sessions, cloud access, lateral movement, and suspicious data movement?
Who communicates with leadership if the event touches regulated data, trial material, or IP?
Who documents the incident well enough to support compliance, cyber insurance, legal review, and board-level reporting?
If the answer is “our IT person will look at it Monday,” then the company does not have a response strategy. It has a ticket queue.
That may sound harsh, but this is where biotech companies get exposed. They buy security tools before they build security operations. They assume that because an alert exists, action will follow. In real incidents, that assumption fails.
Security tools create visibility. Security operations create outcomes.
The difference shows up in the first hour.
In a mature environment, a serious EDR alert triggers a defined process. The alert is triaged. The endpoint is reviewed. The user is validated. The behavior is compared against known threat patterns. Related activity is searched across the environment. Containment is considered quickly. Evidence is preserved. Leadership is informed when business risk is present. The event is documented.
In an immature environment, the alert generates noise. Someone receives an email. Someone else assumes the EDR handled it automatically. The endpoint remains online because nobody wants to disrupt a researcher. The alert is not correlated with identity logs. Nobody checks whether data was accessed. The incident is treated as malware cleanup instead of a business risk event.
That is how a technical alert becomes a leadership problem.
Biotech companies are especially vulnerable to this because their teams are often lean by design. A company under $100M may have sophisticated science, valuable data, regulated workflows, and high investor expectations, but still operate with a small IT team. That team will support users, cloud systems, endpoints, applications, vendors, executive requests, compliance projects, lab connectivity, and security tools at the same time.
That is not a people problem. It is an operating model problem.
Internal IT teams are overloaded because the business keeps asking them to be help desk, infrastructure, cloud engineer, security analyst, incident responder, compliance coordinator, and vendor manager all at once. At some point, leadership has to stop pretending that adding another tool solves a capacity issue.
EDR does not remove the need for judgment.
It increases the need for judgment.
The better the tool, the more important the response process becomes. A high-quality EDR platform can surface suspicious PowerShell behavior, credential theft attempts, unusual parent-child processes, ransomware indicators, or unauthorized persistence. But the tool cannot fully understand your business context. It does not know which machine belongs to a principal investigator. It does not know which shared drive contains sensitive research. It does not know which outage would delay a submission, disrupt a study, or trigger uncomfortable investor questions.
That is where experience matters.
Managed security services should not be positioned as a shortcut for companies that do not care about security. That is weak positioning. The stronger argument is that managed security is a strategic operating model for companies that have outgrown informal response.
A serious MSSP gives biotech leadership three things that tools alone do not provide: experienced security operators, defined response accountability, and coverage beyond business hours.
That does not mean handing over control. In the right model, the MSSP extends the internal team. Internal IT keeps business context. The MSSP brings security operations depth, alert triage, threat investigation, escalation discipline, response playbooks, and guaranteed response times. The point is not to replace internal IT. The point is to stop forcing internal IT to perform a 24×7 security function without the staffing model to support it.
This is where Directors of IT, security leaders, and CISOs should be practical.
Do not evaluate managed security by asking, “Do we already have EDR?”
Ask better questions.
Can we prove every high-severity EDR alert is reviewed within a defined response window?
Do we have after-hours coverage from people who know how to investigate threats, not just acknowledge tickets?
Can we isolate endpoints quickly without creating unnecessary business disruption?
Do we have escalation rules based on data sensitivity, user role, and business impact?
Can we correlate endpoint alerts with identity, cloud, email, firewall, and network activity?
Do we know what gets reported to leadership, legal, compliance, and cyber insurance?
Can we show incident documentation that would hold up under scrutiny?
If those answers are weak, the issue is not whether the EDR platform is good enough. The issue is whether your company can operationalize what the platform finds.
Real-world incidents prove the point. Inotiv, a contract research organization focused on nonclinical and analytical drug discovery and development services, publicly reported a cybersecurity incident it became aware of in August 2025. Its investigation found that a threat actor gained unauthorized access during an August 5–8 window and may have acquired data. The company also stated that it took containment steps, used external cybersecurity specialists, and notified regulators and law enforcement.
That is the real world. Incidents are not just alerts. They become investigations, containment decisions, regulatory communications, legal review, customer trust issues, and leadership events.
Novo Nordisk is another reminder that pharmaceutical and biotech data is a high-value target. Reuters reported in June 2026 that a cyber extortion group claimed it stole more than a terabyte of data, including alleged proprietary drug information, source code, trial data, and internal AI model information; Reuters also noted it could not independently verify the authenticity of the data posted by the group.
For a smaller biotech company, an incident does not need to be that large to become material. A single compromised endpoint tied to research, trial operations, finance, or executive communication can create enough uncertainty to slow decisions and weaken confidence.
That is why “we have EDR” is not a serious answer at the leadership level.
The serious answer is: “We have a response model.”
A strong response model includes defined severity levels, 24×7 alert triage, containment authority, escalation paths, evidence handling, communication procedures, executive reporting, and post-incident improvement. It also includes clear agreement between internal IT and the managed security provider on who does what, when, and under what conditions.
That last part is critical.
A weak MSSP relationship creates more confusion. A strong one removes ambiguity.
Before choosing a managed security provider, biotech leaders should ask for specifics. What is your response SLA for high-severity endpoint alerts? What actions can you take without approval? What actions require approval? How do you handle suspected data exfiltration? How do you document investigations? How do you escalate events involving regulated data, clinical systems, executive accounts, or research repositories? How do you coordinate with our IT team during containment?
Vague answers are a warning sign.
A provider that only forwards alerts is not solving the problem. A provider that cannot explain its investigation process is not mature enough. A provider that talks only about tools is not thinking like an operator.
The right provider talks about decisions, timing, evidence, escalation, and business impact.
For biotech leadership, the question is not whether EDR matters. It does. Endpoint visibility is critical. But endpoint visibility without response maturity creates a dangerous form of confidence. It lets leadership believe the company is protected because alerts exist.
Alerts do not protect intellectual property.
Response does.
As your biotech company grows, the security question changes. Early on, the question may be, “Do we have the right tools?” Later, the question becomes, “Can our operating model keep up with the risk we now carry?”
That is the question leadership should sit with.
Because if your EDR finds the threat but your team cannot respond fast enough, the tool did its job.
Your model failed.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
